Omacor; omega-3-acid ethyl ester 90 (N-3 PUFA) and risk faktors in HIV infected patients treated with HAART with special focus on lipids.

Trial Profile

Omacor; omega-3-acid ethyl ester 90 (N-3 PUFA) and risk faktors in HIV infected patients treated with HAART with special focus on lipids.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Nov 2014

At a glance

  • Drugs Omega-3-acid ethyl esters (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Therapeutic Use
  • Sponsors Pronova BioPharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 26 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top